KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On May 24, 2017, Kura Oncology, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its patent license agreement with the Regents of the University of Michigan (“Michigan”) dated December 22, 2014, as amended (as amended, the “Agreement”), to, among other things, (i) modify the Company’s milestone payment obligations under the Agreement and (ii) reduce the aggregate amount of research that the Company will sponsor over a three-year period at Michigan from $2,715,000 to $2,100,000.

The foregoing is only a summary of the material terms of the Amendment, and does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which will be filed, with confidential terms redacted, with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2017.

About KURA ONCOLOGY, INC. (NASDAQ:KURA)

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

KURA ONCOLOGY, INC. (NASDAQ:KURA) Recent Trading Information

KURA ONCOLOGY, INC. (NASDAQ:KURA) closed its last trading session up +0.05 at 9.40 with shares trading hands.